Celgene’s myelofibrosis approval sets up key launch for BMS

FDA's approval of potential blockbuster Inrebic fedratinib from Celgene sets up a key launch for BMS in myelofibrosis, an indication for which only one other drug is marketed in the U.S.

The agency's decision also boosts the return to shareholders of Impact Biomedicines Inc., the company Celgene Corp. (NASDAQ:CELG)

Read the full 486 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE